For the roughly 39 million people living with HIV worldwide, the daily pill burden of antiretroviral therapy remains a persistent barrier to adherence—and adherence failures drive both treatment resistance and ongoing transmission. A once-weekly oral regimen that performs on par with daily standards could fundamentally reshape long-term HIV management and quality of life.
This Phase 3 randomized trial, published in the New England Journal of Medicine, evaluated a once-weekly oral combination of islatravir and lenacapavir against current daily antiretroviral regimens for HIV-1 treatment in virologically suppressed adults. Islatravir is a nucleoside reverse transcriptase translocation inhibitor (NRTTI), a mechanistic class distinct from older NRTIs, while lenacapavir is a first-in-class capsid inhibitor with a uniquely long pharmacokinetic half-life that makes weekly dosing pharmacologically feasible. The trial assessed non-inferiority on viral suppression endpoints, with safety and tolerability as key secondary outcomes. Both agents are already approved individually in other formulations, giving the combination an established safety foundation entering this efficacy evaluation.
The significance here extends well beyond convenience. Capsid inhibitors like lenacapavir operate at a novel stage of the HIV replication cycle, meaning the combination targets two mechanistically distinct vulnerabilities simultaneously—a design principle that historically reduces resistance emergence. This is only the second oral regimen with a weekly dosing interval to reach Phase 3 evaluation, following decades in which daily dosing was considered a non-negotiable constraint. For clinicians managing patients with adherence challenges, pill fatigue, or stigma-related barriers, a weekly oral option could prove transformative. Limitations to watch include whether the non-inferiority margins hold across diverse subpopulations, particularly those with prior treatment failures or resistance mutations, and whether CD4 count trajectories diverge over longer follow-up. This is a potentially paradigm-shifting data point in HIV therapeutics.